GileadSciences has underperformed the broader market ... The company’s earnings surprise history is mixed. It beat the consensus estimate in three of the past four quarters while missing ...
GileadSciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...